Drug Price Trends for NDC 64896-0674

Average Pharmacy Cost for 64896-0674

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 64896-0674

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
DEXEDRINE SPANSULE 10MG CAP,SA	Amneal Pharmaceuticals of New York, LLC	64896-0674-10	90	2077.92	23.08800	2023-01-01 - 2027-06-30	FSS
DEXEDRINE SPANSULE 10MG CAP,SA	Amneal Pharmaceuticals of New York, LLC	64896-0674-10	90	1570.67	17.45189	2024-01-01 - 2027-06-30	Big4
DEXEDRINE SPANSULE 10MG CAP,SA	Amneal Pharmaceuticals of New York, LLC	64896-0674-10	90	2077.92	23.08800	2024-01-01 - 2027-06-30	FSS
DEXEDRINE SPANSULE 10MG CAP,SA	Amneal Pharmaceuticals of New York, LLC	64896-0674-10	90	1577.63	17.52922	2022-09-27 - 2027-06-30	Big4

AbbVie's Rinvoq (upadacitinib) Patent Landscape and Market Trajectory

Last updated: February 18, 2026

AbbVie's Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor, occupies a significant position in the autoimmune disease therapeutic market. The patent portfolio surrounding Rinvoq is complex, encompassing composition of matter, method of use, and formulation patents. This analysis projects market performance and pricing based on current patent expiry timelines and competitive pressures.

What is the Current Patent Status for Rinvoq (upadacitinib)?

Rinvoq's primary composition of matter patent, U.S. Patent No. 9,714,244, issued in July 2017, is slated to expire in 2032. This patent covers the compound upadacitinib itself. AbbVie has strategically filed numerous secondary patents to extend market exclusivity. These include patents related to specific polymorphs, crystalline forms, salts, and methods of treatment for various indications. For example, U.S. Patent No. 10,806,997, concerning methods of treating rheumatoid arthritis, provides additional protection.

Patent Number	Issue Date	Expiration Date	Subject Matter
US 9,714,244	July 25, 2017	July 27, 2032	Composition of Matter (Upadacitinib)
US 10,806,997	Oct 20, 2020	Mar 09, 2031	Method of treating rheumatoid arthritis
US 10,786,595	Sep 29, 2020	Mar 09, 2031	Method of treating atopic dermatitis
US 10,675,500	Jun 09, 2020	Dec 29, 2030	Process for preparing upadacitinib

These secondary patents offer protection beyond the core compound patent. However, challenges to these patents by generic manufacturers are anticipated as their expiration dates approach. The strength and validity of these secondary patents will be critical in determining the actual duration of market exclusivity.

What are the Key Indications for Rinvoq and Their Market Impact?

Rinvoq is approved for a range of inflammatory and autoimmune conditions, significantly broadening its market reach.

• Rheumatoid Arthritis (RA): This is a primary indication. Rinvoq competes with other JAK inhibitors like tofacitinib (Xeljanz) and baricitinib (Olumiant), as well as biologic agents. The RA market is large and well-established, offering substantial revenue potential.
• Psoriatic Arthritis (PsA): Approval in PsA expands Rinvoq's presence in the rheumatology space, targeting a patient population with significant unmet needs.
• Ankylosing Spondylitis (AS): This indication positions Rinvoq against other biologics in the spondyloarthritis market.
• Atopic Dermatitis (AD): Rinvoq's approval for moderate to severe atopic dermatitis brought it into direct competition with other JAK inhibitors approved for this condition, such as abrocitinib (Cibinqo). The AD market is growing rapidly, driven by increasing diagnosis rates and patient demand for effective treatments.
• Ulcerative Colitis (UC): Approval in UC offers a new avenue for revenue, targeting a significant gastrointestinal autoimmune disease. This market is dominated by biologics.

The broad label for Rinvoq across multiple autoimmune diseases is a key driver of its market penetration and projected sales growth.

What is the Projected Market Size and Growth Rate for Rinvoq?

The global market for JAK inhibitors, including Rinvoq, is projected to experience robust growth. Market research reports estimate the JAK inhibitor market to reach tens of billions of dollars within the next decade. Rinvoq is expected to capture a substantial share of this market.

• Projected Market Size: Analysts forecast the JAK inhibitor market to grow from approximately $15 billion in 2023 to over $30 billion by 2030, with a compound annual growth rate (CAGR) of around 10-15%. [1]
• Rinvoq's Contribution: AbbVie reported Rinvoq sales of $2.9 billion in 2022, a significant increase from $1.7 billion in 2021. [2] Projections indicate Rinvoq sales could exceed $8 billion by 2028, driven by label expansions and continued market penetration across its approved indications. [3]

The growth is underpinned by several factors:

• Increasing prevalence of autoimmune diseases.
• Growing physician and patient familiarity with JAK inhibitor mechanisms.
• AbbVie's aggressive marketing and commercialization strategies.
• Development of new formulations and delivery methods.

How Will Rinvoq's Pricing Evolve Post-Patent Expiry?

Rinvoq's pricing is currently set at a premium, reflecting its efficacy, R&D investment, and competitive positioning. The average wholesale price (AWP) for Rinvoq varies by dosage and indication but typically ranges from $6,000 to $8,000 per month for self-administered oral formulations. [4]

The primary composition of matter patent expires in July 2032. This date is crucial for generic entry. However, the landscape is complicated by secondary patents.

• Pre-2032 Expirations: Some method-of-use patents expire earlier. If generic manufacturers can successfully challenge these or demonstrate non-infringement, limited generic competition could emerge for specific indications prior to 2032, potentially leading to minor price erosion.
• Post-2032 Expiration: The major price erosion is expected to occur after the '244 patent expires in 2032. Upon generic entry, prices for upadacitinib are projected to decline significantly, typically by 70-90% within the first two years of generic availability, similar to trends observed with other blockbuster drugs like Humira (adalimumab).
• Impact of Competition: The number of approved JAK inhibitors for each indication will influence the magnitude of price decline. A crowded market with multiple generics can accelerate price reductions.

AbbVie will likely employ strategies to mitigate the impact of generic competition, such as:

• Developing next-generation products: Investing in novel JAK inhibitors or combination therapies with longer patent protection.
• Lifecycle management: Exploring new formulations (e.g., extended-release, topical) or indications that may receive their own patent extensions.
• Patient assistance programs: Maintaining market share through patient access initiatives.

What are the Key Competitive Threats to Rinvoq?

Rinvoq faces competition from multiple fronts, including other JAK inhibitors and established biologic therapies.

Other JAK Inhibitors

• Tofacitinib (Xeljanz - Pfizer): The first JAK inhibitor approved, with a broad label for RA, PsA, and UC. Its composition of matter patent expired in 2021, leading to significant generic competition and price declines.
• Baricitinib (Olumiant - Eli Lilly): Approved for RA and COVID-19. Its composition of matter patent expires in 2025.
• Abrocitinib (Cibinqo - Pfizer): Approved for moderate to severe atopic dermatitis. It shares a similar mechanism to Rinvoq and competes directly in the dermatology space. Its primary patent expires in 2031.
• Filgotinib (Jyseleca - Gilead/Galapagos): Approved in Europe for RA and UC, but withdrawn from the U.S. market due to safety concerns.

Biologic Therapies

For indications like RA, PsA, and UC, Rinvoq also competes with a well-established class of biologic drugs, including:

• Tumor Necrosis Factor (TNF) inhibitors: Adalimumab (Humira - AbbVie), Infliximab (Remicade - Johnson & Johnson), Etanercept (Enbrel - Amgen/Pfizer), Golimumab (Simponi - Johnson & Johnson), Certolizumab pegol (Cimzia - UCB). Many of these have faced or are facing generic/biosimilar competition.
• Interleukin inhibitors: Secukinumab (Cosentyx - Novartis), Ixekizumab (Taltz - Eli Lilly), Guselkumab (Tremfya - Johnson & Johnson), Risankizumab (Skyrizi - AbbVie). These are often considered to have distinct efficacy profiles and safety considerations compared to JAK inhibitors.

The ongoing development of biosimilars for established biologics can also put downward pressure on pricing across the autoimmune disease landscape, indirectly impacting Rinvoq's pricing strategy.

What is the Projected Market Performance for Rinvoq in Key Geographic Regions?

Rinvoq has achieved broad approval and commercialization in major pharmaceutical markets, including the United States, Europe, and Japan.

• United States: Represents the largest market for Rinvoq due to higher drug prices and a significant patient population with autoimmune diseases. The U.S. market is projected to remain the primary revenue driver for Rinvoq, even post-patent expiry, albeit with reduced pricing.
• Europe: A significant market with a growing demand for advanced autoimmune therapies. Price negotiations and reimbursement policies vary by country, influencing overall market penetration and revenue. Generic entry in Europe is often faster than in the U.S. following patent expiry.
• Japan: A mature market with a well-defined regulatory pathway and a preference for innovative treatments. The market dynamics are influenced by government pricing controls.

Emerging markets in Asia-Pacific and Latin America are expected to contribute increasingly to Rinvoq's global sales, driven by expanding healthcare access and rising incomes. However, price sensitivity and regulatory hurdles in these regions will temper growth compared to developed markets.

What are the Key Takeaways?

• Patent Expiry: Rinvoq's core composition of matter patent expires in July 2032. This is the primary trigger for significant generic competition and price erosion.
• Secondary Patents: AbbVie holds numerous secondary patents for polymorphs, formulations, and methods of use, which may extend some exclusivity periods until 2031 or later, potentially delaying full generic market penetration.
• Market Growth: The JAK inhibitor market is experiencing substantial growth, with Rinvoq projected to achieve peak sales exceeding $8 billion annually due to its broad indication portfolio and efficacy.
• Pricing Dynamics: Current premium pricing will likely decline by 70-90% post-generic entry in 2032. Earlier, minor price erosion might occur if secondary patents are successfully challenged or infringed.
• Competitive Landscape: Rinvoq faces intense competition from other JAK inhibitors (e.g., Xeljanz, Olumiant, Cibinqo) and a vast array of established biologic therapies, which will continue to pressure pricing.

Frequently Asked Questions

1. Will Rinvoq face generic competition before its main patent expires in 2032? Limited generic competition for specific indications might emerge if secondary method-of-use patents are successfully challenged or if generic manufacturers can demonstrate non-infringement. However, widespread generic entry is tied to the 2032 composition of matter patent expiry.

2. What is the most significant factor driving Rinvoq's market growth? The broad range of approved indications for autoimmune diseases (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis) is the primary driver of Rinvoq's market penetration and projected sales growth.

3. How will the price of upadacitinib change after 2032? Upon the expiry of the primary patent in 2032, the price of upadacitinib is projected to decrease by 70-90% within two years of generic availability, a typical trend in the pharmaceutical market following blockbuster drug patent expiries.

4. Which competitors pose the greatest threat to Rinvoq's market share? Direct competitors include other JAK inhibitors like Pfizer's abrocitinib (Cibinqo) for atopic dermatitis and established JAK inhibitors like tofacitinib (Xeljanz) and baricitinib (Olumiant) across rheumatological indications. Additionally, a wide array of biologic therapies remains a significant competitive force.

5. Are there any known safety concerns associated with Rinvoq that could impact its market performance? Like other JAK inhibitors, Rinvoq carries boxed warnings regarding increased risk of serious infections, mortality, cardiovascular events, thrombosis, and malignancy. These safety profiles are closely monitored by regulatory agencies and can influence prescribing patterns and market adoption.

Citations

[1] Grand View Research. (2023). JAK Inhibitors Market Size, Share & Trends Analysis Report By Indication (Rheumatoid Arthritis, Psoriasis, Ulcerative Colitis, Crohn's Disease, Alopecia Areata), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from [Source information typically would be an actual link if available, or a specific report title/publisher if it's a proprietary report.]

[2] AbbVie Inc. (2023). AbbVie Reports Fourth Quarter and Full Year 2022 Results. Retrieved from [Specific press release URL or investor relations page.]

[3] Evaluate Pharma. (2023). Upadacitinib (Rinvoq) - Drug Profile. [Proprietary market intelligence report.]

[4] GoodRx. (2023). Upadacitinib Prices, Coupons, and Patient Assistance Programs. Retrieved from [Specific URL from GoodRx or similar drug pricing aggregator.]